ClinicalTrials.gg
CompletedNCT03055403Updated Nov 30, 2021

First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects

A Phase 1 interventional study of M201-A Injection and Placebo in Healthy Volunteers, sponsored by Yuji KUMAGAI. Completed at 1 site in Japan. Open to male participants aged 20 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-30.

Sponsored by Yuji KUMAGAI · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Male
01

Study summary

This Phase I first-in-human is designed to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of M201-A administered by single continuous intravenous injection in Healthy Japanese subjects.

Read the detailed description

Not Provided

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

This is the only study on the registry with Yuji KUMAGAI as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  • Japanese Healthy Male subjects
  • Age 20 to less than 40 years of age
  • (BMI) of 18.5 to less than 25.0 kg/m2
  • Written must be obtained on a voluntary basis before any assessment is performed.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  • Presence or past medical history of hepatic impairments, renal impairments, cardiovascular disease, gastrointestinal disease and others which are inappropriate for participating in this clinical trial
  • Past medical history of cancer, cerebral infarction or cardiac infarction
  • Presence or past medical history of allergic reactions or idiosyncrasies to food, medicinal substance and metallic materials
  • > 450ms at the screening examination
  • NT-proBNP > 125 pg/mL at the screening examination
  • Any risk factors of Torsades de Pointes including such as heart failure, hypokalemia, long QT interval syndrome due to family medical history
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    M201-A Injection

    Active Substance: M201-A Route of administration: continuous intravenous injection

    Drug: M201-A Injection

  • Placebo comparator
    Placebo

    Saline Placebo for M201-A Route of administration: continuous intravenous injection

    Drug: Placebo

Interventions

  • DrugM201Studies of M201M201 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Active Substance: M201-A Route of administration: continuous intravenous injection

  • DrugPlacebo

    Saline Placebo for M201-A Route of administration: continuous intravenous injection

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events as a measure of safety and tolerability

    adverse events, serious adverse events, physical examinations, vital sign measurements, 12-lead ECGs, Holter ECG, clinical laboratory safety tests (including hematology, chemistry, and urinalysis), recording of concomitant medications and procedures.

    Time frame: Throughout the study duration (up to day8)

Secondary outcomes

  1. Pharmacokinetics-Cmax

    Observed maximum plasma concentration (Cmax) of M201-A

    Time frame: Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A

  2. Pharmacokinetics-Tmax

    Time to Cmax (Tmax) of M201-A

    Time frame: Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A

  3. Pharmacokinetics-AUC0-24

    Area under the plasma concentration-time curve from time zero to 24hour of M201-A

    Time frame: Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A

  4. Pharmacokinetics-AUC0-t

    -Area under the plasma concentration-time curve calculated from time zero to the last measured time point (AUC0-t) of M201-A

    Time frame: Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A

  5. Pharmacokinetics-AUC0-∞

    Area under the plasma concentration-time curve calculated from time zero to infinity (AUC0-∞) of M201-A

    Time frame: Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A

  6. Pharmacokinetics-t1/2

    Elimination half-life (t1/2) of M201-A

    Time frame: Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A

  7. Pharmacokinetics-CL

    Apparent clearance of drug from plasma (CL) of M201-A

    Time frame: Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A

  8. Pharmacokinetics-Vd

    Apparent volume of distribution during the terminal phase (Vd) of M201-A

    Time frame: Predose, 0, 5, 15, 30, 60, 120, 240, 480 minutes and 24 hours after the IV infusion of M201-A

  9. Pharmacokinetics-E0-24

    Amount of drug excreted in urine from time zero to 24hour of M201-A

    Time frame: up to 24 hours

  10. Pharmacokinetics-Ae

    Urinary excretion rate of M201-A

    Time frame: up to 24 hours

07

Study locations

1 site
  • Clinical Trial Center, Kitasato University Hospital, THE KITASATO INSTITUTE
    Sagamihara, Kanagawa 252-0375, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Nov 2017, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2017
First posted
Feb 16, 2017
StartActual
Feb 17, 2017
Primary completionActual
Nov 28, 2017
CompletionActual
Nov 28, 2017
Last update
Nov 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03055403
Lead sponsor
Yuji KUMAGAI
Collaborators
Aetas Pharma Co. Ltd.
Responsible party
Yuji KUMAGAI (Professor, Kitasato University) — Sponsor-investigator
First posted
Feb 16, 2017
Start date
Feb 17, 2017
Primary completion
Nov 28, 2017
Completion
Nov 28, 2017
Last update
Nov 30, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: M201

Start the discussion